Cancer cachexia is a devastating metabolic syndrome for which there are no approved treatments. Li and colleagues developed an RNA-targeted therapy, which ameliorates cachectic symptoms, reduces inflammation, and extends survival in mouse cancer models. The study provides an approach for treating cancer cachexia and paves the road for clinical studies.